LLY vs MRK — Key Metrics

Metric LLY (ELI LILLY & CO) MRK (MERCK & CO INC)
Price1382.75137.78
Market Cap1.3 Trillion339.66 Billion
P/E (TTM)44.82137.78
P/B (Quarterly)32.098.257
P/S (TTM)15.045.04
Net Profit Margin (TTM)31.93.6
Gross Margin (TTM)83.671.8
ROE (TTM)83.65.3
Revenue Growth YoY (TTM)n/an/a

Upfront Investment - S&P 500 Stock Comparison & AI Analysis

AI-powered analysis and comparison tools for S&P 500 stocks, helping investors make data-driven decisions with delayed market data and portfolio modeling.

ELI LILLY & CO
vs
 
MERCK & CO INC
 
ELI LILLY & CO
vs
 
MERCK & CO INC
Performance Comparison
AI Model Recommendation
LLY · ELI LILLY & CO

Underperform

-30
UnderperformOutperform
MRK · MERCK & CO INC

Greatly Outperform

82
UnderperformOutperform
Recommendation Summary

Stock LLY is projected to underperform the market, stock MRK is projected to greatly outperform the market. Upfront Recommendation: MRK.

Financial Metrics
Prices delayed ~15 min
LLY Metrics MRK
$1,382.75 Price $137.78
— Market Capitalization —
44.82 Price to Earnings Ratio 137.78
15.04 Price to Sales 5.04
66.16 Price to FCF Ratio 23.03
17.99 Price to Gross Profit 7.03
84.59 Price to R&D 11.04
19.93 Price to Current Assets 8.72

LLY vs MRK at a glance

ELI Lilly & CO (LLY) and Merck & CO INC (MRK) are both Drug Manufacturers - General companies in the Healthcare sector. LLY is the larger, at $1.3 trillion in market value against $339.7 billion for MRK, about 3.8 times the size.

On trailing-twelve-month figures, LLY trades at 44.8 times trailing earnings and MRK at 137.8; net profit margins are 31.9% and 3.6%.

The Upfront Investment model currently rates LLY Underperform and MRK Greatly Outperform as of November 18, 2026. The rating ranks the model's medium-term return forecast against the other stocks it scores; it is a statistical forecast, not investment advice.